Oral Bisphosphonates Induced Osteonecrosis of the Mandible : a Case Report.
- Author:
Hyo jeong SON
1
;
Ho yeol JANG
;
Yun seon KEUM
;
Jang yeol LEE
;
Hyoun Chull KIM
;
Sang chull LEE
Author Information
1. Department of oral and maxillofacial surgery, LivingWell Dental Hospital, Korea. livingwell@paran.com
- Publication Type:Case Report
- Keywords:
Osteoporosis;
Oral bisphosphonates;
Osteonecrosis;
Complication
- MeSH:
Adhesives;
Aged, 80 and over;
Apoptosis;
Crowns;
Dentists;
Diphosphonates;
DNA-Directed DNA Polymerase;
Follow-Up Studies;
Humans;
Hypercalcemia;
Mandible;
Molar;
Multiple Myeloma;
Oral Hygiene;
Osteoclasts;
Osteonecrosis;
Osteoporosis;
Signal Transduction
- From:Journal of the Korean Association of Oral and Maxillofacial Surgeons
2009;35(2):106-111
- CountryRepublic of Korea
- Language:English
-
Abstract:
Bisphosphonates have been approved for Paget's disease, cancer - related hypercalcemia, bone involvement in multiple myeloma or solid tumors and osteoporosis. Although, underlying pathophysiological mechanisms remain unclear, it seems that bisphosphonates inhibit osteoclast precursor cells, modulate migratory and adhesive characteristics and induce apoptosis of osteoclasts. Furthermore impacts on angiogenesis, microenvironment and signal transduction between osteoclasts and osteoblasts. In this report, we present a case of oral bisphosphonates induced osteonecrosis of the mandible in a 84-year-old patient who received for two years. Two tapered screw vent implants(Zimmer, USA) were placed in the area of first and second molar. Two weeks later after crowns restored, some inflammatory signs and symptoms were observed on the second molar area. Sequestrum was formed and the sequestrum was removed with the implant. Frequent follow-up checks and oral hygiene maintenances were done and the first molar implant was restored. There is insufficient evidence suggests that duration of oral bisphosphonate therapy correlates with the development and severity of osteonecrosis. Therefore, dentists should not overlook the possibility of development of bisphosphonate induced osteonecrosis in patients who have taken oral forms of medication for less than three years.
